The invention provides a gene sequence which can encode and express adenovirus hexon protein in vitro, and is represented as SEQ ID NO: 3. Also invented a protein which was translated and expressed by the gene sequence according to the invention, and the invention also relates to the use of the protein as an antigen to immunize rabbits to obtain a polyclonal antibody. The antibody mentioned above can detect adenovirus with high sensitivity and specificity.

Disclosed herein relates to a replication competent recombinant adenovirus comprising restriction enzyme sites in an E3 region to insert a gene of interest. Also disclosed herein is a method for generating the replication competent recombinant adenovirus and a pharmaceutical composition comprising the adenovirus for use in treating a disease or a condition.

Described herein are cell lines for recombinant adeno-associated virus (AAV) production, cell lines for AAV-implemented protein production, and cell lines for use in titering AAV; methods of making each of those cell lines; and methods of using each of those cell lines. In some aspects, the cell lines disclosed herein may be used in a manufacturing process that is seed virus-free, helper virus-free, and transfection-free that uses synthetic elements to control viral genes in a stable cell line.

The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.

The present invention relates to a cell line for producing an adenovirus having a limited autoreplication capability, and a method of preparing the same, and more particularly, to a cell line for producing an adenovirus having no autoreplication capability by expressing at least one selected from an adenoviral E1 protein and an E1A or E1B protein, and a method of preparing the same. Also, the present invention relates to the use of the cell line expressing at least one selected from the adenoviral E1 protein and the E1A or E1B protein.

Provided are recombinant adeno-associated virus (rAAV) compositions for the expression of antibodies (e.g., anti-complement component 5 (C5) antibodies) in cells, and methods of treating disorders with the same (e.g., disorders associated with C5 activity (e.g., Paroxysmal Nocturnal Hemoglobinuria)). Also provided are compositions, systems and methods for making the rAAV compositions.

An agent which promotes homology directed DNA repair for use in haematopoietic stem and/or progenitor cell gene therapy, wherein said haematopoietic stem cells are gene edited. Use of an agent which promotes homology directed DNA repair, for increasing the survival and/or engraftment of gene edited haematopoietic stemand/or progenitorcells or for increasing the efficiency of gene editing of haematopoietic stem and/or progenitor cells.

This invention provides compositions of a viral vector system containing a survivin promotor configured for expressing a reporter gene, wherein the reporter gene is differentially expressed in benign and malignant uterine masses and malignant uterine sarcomas can be bioimaged by preferential labeling with a radiotracer.

Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.